Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ANSWER
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
- NCT04455594 ↗
- Unknown
- The First Affiliated Hospital of Guangzhou Medical University
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ANSWER (stage IIIA-N2 EGFR-mutated NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ANSWER so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC: a Multicenter, Open-label, Phase II Randomized Controlled Trial
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Non-Small Cell Lung Cancer Stage IIIA
- Interventions
- Almonertinib; Erlotinib; Cisplatin; Carboplatin; Pemetrexed
- Arms
- Almonertinib · Experimental
- Investigator-choice therapy (Erlotinib or Chemotherapy) · Active comparator
- Enrollment
- 168 (estimated)
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2020 (estimated)
- Primary completion
- Jan 2023 (estimated)
- Results posted
- No
- Registry record
- NCT04455594 · updated Jul 2, 2020